11:19 AM EDT, 08/02/2024 (MT Newswires) -- Agilent Technologies ( A ) said Friday that the US Food and Drug Administration has approved its MAGE-A4 IHC 1F9 pharmDx as a diagnostic tool for identifying synovial sarcoma patients who may be treated with Adaptimmune Therapeutics' ( ADAP ) Tecelra, a MAGE-A4-directed engineered T-cell Receptor therapy.

MAGE-A4, or melanoma-associated antigen A4, is a cancer-testis antigen found in various cancers, including synovial sarcoma, according to the company statement.

The company's diagnostic test detects MAGE-A4 in synovial sarcoma patients for potential treatment with Tecelra, Agilent ( A ) said.

Agilent ( A ) and Adaptimmune shares fell 4.2% and 11% respectively in recent trading Friday.

Price: 136.91, Change: -5.95, Percent Change: -4.16